Technical Analysis for GH - Guardant Health, Inc.

Grade Last Price % Change Price Change
grade A 36.24 -8.97% -3.57
GH closed down 8.97 percent on Monday, December 17, 2018, on 1.24 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Down Down
See historical GH trend table...

Date Alert Name Type % Chg
Dec 17 Fell Below 50 DMA Bearish 0.00%
Dec 17 Wide Bands Range Expansion 0.00%
Dec 17 Down 3 Days in a Row Weakness 0.00%
Dec 17 Down 4 Days in a Row Weakness 0.00%
Dec 14 Fell Below 20 DMA Bearish -8.97%
Dec 14 MACD Bearish Signal Line Cross Bearish -8.97%
Dec 14 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -8.97%
Dec 14 Multiple of Ten Bearish Other -8.97%
Dec 14 Wide Bands Range Expansion -8.97%
Dec 14 Down 3 Days in a Row Weakness -8.97%

Older signals for GH ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Its Guardant Health Oncology Platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. In pursuit of its goal to manage cancer across all stages of the disease, Guardant Health has launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2, respectively. Since its launch in 2014, Guardant360 has been used by more than 5,000 oncologists, over 40 biopharmaceutical companies and all 27 of the National Comprehensive Cancer Network centers.
Is GH a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 49.55
52 Week Low 27.04
Average Volume 608,763
200-Day Moving Average 0.0
50-Day Moving Average 37.1626
20-Day Moving Average 39.8665
10-Day Moving Average 42.729
Average True Range 3.66
ADX 19.34
+DI 19.7283
-DI 24.5723
Chandelier Exit (Long, 3 ATRs ) 38.57
Chandelier Exit (Short, 3 ATRs ) 42.04
Upper Bollinger Band 47.2713
Lower Bollinger Band 32.4617
Percent B (%b) 0.26
BandWidth 37.147981
MACD Line 1.1465
MACD Signal Line 1.6756
MACD Histogram -0.5291
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 41.66
Resistance 3 (R3) 42.24 41.02 40.75
Resistance 2 (R2) 41.02 39.64 40.73 40.45
Resistance 1 (R1) 38.63 38.79 38.02 38.05 40.15
Pivot Point 37.41 37.41 37.11 37.12 37.41
Support 1 (S1) 35.02 36.03 34.41 34.44 32.33
Support 2 (S2) 33.80 35.18 33.51 32.03
Support 3 (S3) 31.41 33.80 31.73
Support 4 (S4) 30.83